Lexun Wang
Overview
Explore the profile of Lexun Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li T, Lin S, Zhu Y, Ye D, Rong X, Wang L
Cell Death Discov
. 2025 Mar;
11(1):102.
PMID: 40087290
CCAAT/enhancer-binding protein delta (CEBPD), as an evolutionarily conserved protein in mammals, belongs to the CEBP transcription factor family, which modulates many biological processes. The diversity of CEBPD functions partly depends...
2.
Wang L, Lin S, Wei Q, Li T, Mo Q, Bai R, et al.
Int Immunopharmacol
. 2025 Feb;
151:114296.
PMID: 39983422
Myocardial infarction (MI) remains a leading cause of global health burden, and adverse cardiac remodeling after MI seriously affects patient recovery. Macrophages play an important role in the cardiac remodeling...
3.
Huang Y, Liang M, Liao Y, Ji Z, Lin W, Pu X, et al.
Metabolites
. 2024 Sep;
14(9).
PMID: 39330516
This study focused on exploring the effects of SW033291, an inhibitor of 15-hydroxyprostaglandin dehydrogenase, on type 2 diabetes mellitus (T2DM) mice from a comprehensive perspective. Studies have demonstrated that SW033291...
4.
Liu Y, Zhan W, Wang L, Wang W
Curr Med Chem
. 2024 Feb;
PMID: 38409700
Diabetic coronary heart disease is a global medical problem that poses a serious threat to human health, and its pathogenesis is complex and interconnected. Nicotinamide adenine dinucleotide (NAD) is an...
5.
Lin S, Zhang S, Zhan A, Feng J, Yang Q, Li T, et al.
Eur J Pharmacol
. 2024 Feb;
967:176395.
PMID: 38350592
Cardiac fibrosis, the hallmark of cardiovascular disease, is characterized by excessive deposition of extracellular matrix in the heart. Emerging evidence indicates that cardiac fibroblasts (CFs) play pivotal roles in driving...
6.
Shao X, Zeng W, Wang Q, Liu S, Guo Q, Luo D, et al.
J Ethnopharmacol
. 2024 Jan;
324:117705.
PMID: 38219878
Background: Research on the Chinese herbal formula Fufang Zhenzhu Tiaozhi (FTZ) has demonstrated its effectiveness in treating hyperlipidemia and glycolipid metabolic disorders. Additionally, FTZ has shown inhibitory effects on oxidative...
7.
Liang M, Zhan W, Wang L, Bei W, Wang W
Diabetes Metab Syndr Obes
. 2023 Oct;
16:3223-3234.
PMID: 37867629
Purpose: Ginsenoside Rb1 (Rb1), one of the crucial bioactive constituents in C. A. Mey., possesses anti-type 2 diabetes mellitus (T2DM) property. Nevertheless, the precise mechanism, particularly the impact of Rb1...
8.
Yan M, Liu S, Zeng W, Guo Q, Mei Y, Shao X, et al.
Biomed Pharmacother
. 2023 Jun;
164:114919.
PMID: 37302318
Diabetic cardiomyopathy (DCM) is an important complication leading to the death of patients with diabetes, but there is no effective strategy for clinical treatments. Fufang Zhenzhu Tiaozhi (FTZ) is a...
9.
Wang W, Liang M, Wang L, Bei W, Guo J
Bioorg Chem
. 2023 Jun;
137:106646.
PMID: 37285764
Type 2 diabetes mellitus (T2DM) is a rapidly growing epidemic that results in increased morbidity, mortality, and soaring medical costs. Prostaglandin E (PGE), a vital lipid mediator, has been reported...
10.
Zhong Q, Yin J, Wang K, Chen X, Wang H, Hu X, et al.
J Ethnopharmacol
. 2023 May;
315:116564.
PMID: 37244407
Ethnopharmacological Relevance: Fufang-Zhenzhu-Tiaozhi capsule (FTZ), a Traditional Chinese Medicine (TCM) patent prescription commonly used in clinical practice, has a significant curative effect on hyperglycemia and hyperlipidemia. Previous studies have shown...